134 related articles for article (PubMed ID: 33821961)
1. MMRFBiolinks: an R-package for integrating and analyzing MMRF-CoMMpass data.
Settino M; Cannataro M
Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33821961
[TBL] [Abstract][Full Text] [Related]
2. Using MMRFBiolinks R-Package for Discovering Prognostic Markers in Multiple Myeloma.
Settino M; Cannataro M
Methods Mol Biol; 2022; 2401():289-314. PubMed ID: 34902136
[TBL] [Abstract][Full Text] [Related]
3. Identification of Key Genes and Pathways in Myeloma side population cells by Bioinformatics Analysis.
Yang Q; Li K; Li X; Liu J
Int J Med Sci; 2020; 17(14):2063-2076. PubMed ID: 32922167
[No Abstract] [Full Text] [Related]
4. New insights into genetic characteristics between multiple myeloma and COVID-19: An integrative bioinformatics analysis of gene expression omnibus microarray and the cancer genome atlas data.
Wang F; Liu R; Yang J; Chen B
Int J Lab Hematol; 2021 Dec; 43(6):1325-1333. PubMed ID: 34623759
[TBL] [Abstract][Full Text] [Related]
5. Next Generation Sequencing-based Validation of the Revised International Staging System for Multiple Myeloma: An Analysis of the MMRF CoMMpass Study.
Goldsmith SR; Fiala MA; Dukeman J; Ghobadi A; Stockerl-Goldstein K; Schroeder MA; Tomasson M; Wildes TM; Vij R
Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):285-289. PubMed ID: 30792096
[TBL] [Abstract][Full Text] [Related]
6. Development of an RNA sequencing-based prognostic gene signature in multiple myeloma.
Zamani-Ahmadmahmudi M; Nassiri SM; Soltaninezhad F
Br J Haematol; 2021 Jan; 192(2):310-321. PubMed ID: 32410217
[TBL] [Abstract][Full Text] [Related]
7. Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma.
Laganà A; Perumal D; Melnekoff D; Readhead B; Kidd BA; Leshchenko V; Kuo PY; Keats J; DeRome M; Yesil J; Auclair D; Lonial S; Chari A; Cho HJ; Barlogie B; Jagannath S; Dudley JT; Parekh S
Leukemia; 2018 Jan; 32(1):120-130. PubMed ID: 28642592
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of esterase gene expression in multiple myeloma.
Kumari R; Majumder MM; Lievonen J; Silvennoinen R; Anttila P; Nupponen NN; Lehmann F; Heckman CA
Br J Cancer; 2021 Apr; 124(8):1428-1436. PubMed ID: 33531688
[TBL] [Abstract][Full Text] [Related]
9. One-lincRNA and five-mRNA based signature for prognosis of multiple myeloma patients undergoing proteasome inhibitors therapy.
Liu Y; Yang N; Peng X; Liu G; Zhong H; Liu L
Biomed Pharmacother; 2019 Oct; 118():109254. PubMed ID: 31357080
[TBL] [Abstract][Full Text] [Related]
10. EZH2 Overexpression in Multiple Myeloma: Prognostic Value, Correlation With Clinical Characteristics, and Possible Mechanisms.
Goldsmith SR; Fiala MA; O'Neal J; Souroullas GP; Toama W; Vij R; Schroeder MA
Clin Lymphoma Myeloma Leuk; 2019 Nov; 19(11):744-750. PubMed ID: 31551170
[TBL] [Abstract][Full Text] [Related]
11. Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival.
Nair B; Shaughnessy JD; Zhou Y; Astrid-Cartron M; Qu P; van Rhee F; Anaissie E; Alsayed Y; Waheed S; Hollmig K; Szymonifka J; Petty N; Hoering A; Barlogie B
Blood; 2009 Jun; 113(26):6572-5. PubMed ID: 19389881
[TBL] [Abstract][Full Text] [Related]
12. A nomogram for predicting prognosis of multiple myeloma patients based on a ubiquitin-proteasome gene signature.
Ji D; Liu Y; Sun W; Shi Q; Chen G; Song Z; Jiang Y
Aging (Albany NY); 2022 Dec; 14(24):9951-9968. PubMed ID: 36534449
[TBL] [Abstract][Full Text] [Related]
13. New functionalities in the TCGAbiolinks package for the study and integration of cancer data from GDC and GTEx.
Mounir M; Lucchetta M; Silva TC; Olsen C; Bontempi G; Chen X; Noushmehr H; Colaprico A; Papaleo E
PLoS Comput Biol; 2019 Mar; 15(3):e1006701. PubMed ID: 30835723
[TBL] [Abstract][Full Text] [Related]
14. Company Profile: Multiple Myeloma Research Foundation.
Giusti K
Per Med; 2012 May; 9(3):333-336. PubMed ID: 29758781
[TBL] [Abstract][Full Text] [Related]
15. Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1.
Garderet L; Laubach JP; Stoppa AM; Hari P; Cavo M; Ludwig H; Mateos MV; Luptakova K; Lin J; Yung G; van de Velde H; Berg D; Moreau P; Richardson PG
Leukemia; 2018 Sep; 32(9):2032-2036. PubMed ID: 29568098
[No Abstract] [Full Text] [Related]
16. Myeloma researchers gain genome, new targets, and new concerns.
Brower V
J Natl Cancer Inst; 2011 Jul; 103(14):1082-5. PubMed ID: 21737696
[No Abstract] [Full Text] [Related]
17. Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma.
Anguiano A; Tuchman SA; Acharya C; Salter K; Gasparetto C; Zhan F; Dhodapkar M; Nevins J; Barlogie B; Shaughnessy JD; Potti A
J Clin Oncol; 2009 Sep; 27(25):4197-203. PubMed ID: 19636021
[TBL] [Abstract][Full Text] [Related]
18. MPC-1 expression in myeloma cells is associated with the efficacy of bortezomib therapy.
Kurihara K; Iriyama N; Miura K; Uchino Y; Takahashi H; Nakagawa M; Iizuka K; Hamada T; Koike T; Hatta Y; Nakayama T; Takei M
Med Oncol; 2019 Jul; 36(9):75. PubMed ID: 31342211
[TBL] [Abstract][Full Text] [Related]
19. GDCRNATools: an R/Bioconductor package for integrative analysis of lncRNA, miRNA and mRNA data in GDC.
Li R; Qu H; Wang S; Wei J; Zhang L; Ma R; Lu J; Zhu J; Zhong WD; Jia Z
Bioinformatics; 2018 Jul; 34(14):2515-2517. PubMed ID: 29509844
[TBL] [Abstract][Full Text] [Related]
20. miRNA-seq identification and clinical validation of CD138+ and circulating miR-25 in treatment response of multiple myeloma.
Papadimitriou MA; Soureas K; Papanota AM; Tsiakanikas P; Adamopoulos PG; Ntanasis-Stathopoulos I; Malandrakis P; Gavriatopoulou M; Sideris DC; Kastritis E; Avgeris M; Dimopoulos MA; Terpos E; Scorilas A
J Transl Med; 2023 Apr; 21(1):245. PubMed ID: 37024879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
